How Can Policymakers Overcome the Hurdles to Scaling up Antibody Manufacturing?
The difficult manufacturing issues involved in the therapeutic antibody context, and what might be done to address them.
research
-
Read more: How Can Policymakers Overcome the Hurdles to Scaling up Antibody Manufacturing? -
Read more: Why Aren’t Therapeutic Antibodies Being Used More to Treat COVID-19? Why Aren’t Therapeutic Antibodies Being Used More to Treat COVID-19?
The rapid development of therapeutic antibodies is a triumph of biomedical innovation. But they won’t help unless they make it to patients.
-
Read more: Computational Psychiatry for Precision Sentencing in Criminal Law Computational Psychiatry for Precision Sentencing in Criminal Law
Deep phenotyping offers the criminal justice system the tools to improve public safety, identify low-risk offenders, and reduce recidivism.
-
Read more: Deep Phenotyping Could Help Solve the Mental Health Care Crisis Deep Phenotyping Could Help Solve the Mental Health Care Crisis
While moving too quickly with new technologies carries ethical and societal risks, moving too slowly could leave vulnerable people behind.
-
Read more: Incidental Findings in Deep Phenotyping Research: Legal and Ethical Considerations Incidental Findings in Deep Phenotyping Research: Legal and Ethical Considerations
What obligations do researchers have to disclose potentially life-altering incidental findings as they happen in real time?
-
Read more: Unique Challenges to Informed Consent in Deep Phenotyping Research Unique Challenges to Informed Consent in Deep Phenotyping Research
Obtaining voluntary competent informed consent is a critical aspect to conducting ethical deep phenotyping research.
-
Read more: Lessons Learned from Deep Phenotyping Patients with Rare Psychiatric Disorders Lessons Learned from Deep Phenotyping Patients with Rare Psychiatric Disorders
It is important to respect the wishes of the various parties involved when describing patients with potentially stigmatizing diagnoses.
-
Read more: “Actionability” and the Ethics of Communicating Results to Study Participants “Actionability” and the Ethics of Communicating Results to Study Participants
What data may be considered “actionable” for the physician to disclose to the patient, and how might this be done?
-
Read more: What Can Policymakers Learn from the Slow COVID-19 Vaccine Rollout? What Can Policymakers Learn from the Slow COVID-19 Vaccine Rollout?
In this post we explain what went wrong and how policymakers can correct course for COVID-19 and avoid such disasters in the future.
-
Read more: From 9/11 to COVID-19: A Brief History of FDA Emergency Use Authorization From 9/11 to COVID-19: A Brief History of FDA Emergency Use Authorization
The history of EUA involves fundamental questions about the role of public officials, scientific expertise, and administrative norms in times of crisis.
